55.04
1.35 (2.51%)
| Previous Close | 53.69 |
| Volume | 1,499,949 |
| Price / Sales | 61.27 |
| 52 Weeks Range |
| Operating Margin (TTM) | -9,856.30% |
| Diluted EPS (TTM) | -5.29 |
| Quarterly Revenue Growth (YOY) | 89.10% |
| Total Debt/Equity (MRQ) | 727.94% |
| Current Ratio (MRQ) | 5.99 |
| Operating Cash Flow (TTM) | -398.00 M |
| Levered Free Cash Flow (TTM) | -241.41 M |
| Return on Assets (TTM) | -34.12% |
AIStockmoo Score
| Value 30% | -2.5 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -2.5 |
| Timing 30% | -3.4 |
| AI Technical info | NA |
| Technical Oscillators info | -4.0 |
| Technical Moving Averages info | -2.5 |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| Analyst Consensus info | 0.0 |
| News Mood info | NA |
| Smart Money 20% | -0.5 |
| Insider Activity info | -0.5 |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Environment | ×1.13 |
| Macro Environment info | -1.3 |
| Sector vs Market (6M) | -26.9% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | 5.0 |
| Final Score | -2.65 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cytokinetics, Incorporated | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CYTK | - | - | - | - |
| IBRX | - | - | - | - |
| VIR | - | - | - | 2.29 |
| RLMD | - | - | - | 2.15 |
| CNTN | - | - | - | 0.290 |
| SLS | - | - | - | 11.78 |
Select this tab to load the latest available analysis.
|
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.72% |
| % Held by Institutions | 119.58% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BLUM ROBERT I | - | 62.03 | -7,500 | -465,225 |
| MALIK FADY IBRAHAM | - | 62.31 | -3,500 | -218,085 |
| Aggregate Net Quantity | -11,000 | |||
| Aggregate Net Value ($) | -683,310 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 62.12 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MALIK FADY IBRAHAM | Officer | 03 Nov 2026 | Sell (-) | 3,500 | 62.31 | 218,085 |
| MALIK FADY IBRAHAM | Officer | 03 Nov 2026 | Option execute | 3,500 | - | - |
| BLUM ROBERT I | Officer | 02 Nov 2026 | Sell (-) | 7,500 | 62.03 | 465,225 |
| BLUM ROBERT I | Officer | 02 Nov 2026 | Option execute | 7,500 | - | - |
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |